Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm
June 14 2022 - 7:30AM
Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera
Biopharma”), a biopharmaceutical company creating next-generation
immune therapies that focus on immune restoration and homeostasis,
today announced the appointment of Certified Public Accountants, BF
Borgers CPA PC as the Company’s independent accountant to audit the
balance sheet of the Company as of December 31, 2021, and the
related statements of operations, stockholders’ equity and income,
and cash flows for the period ended December 31, 2021.
About Statera BiopharmaStatera
Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage
biopharmaceutical company developing novel immunotherapies
targeting autoimmune, neutropenia/anemia, emerging viruses and
cancers based on a proprietary platform designed to rebalance the
body’s immune system and restore homeostasis. Statera Biopharma has
a large platform of toll-like receptor (TLR) agonists
with TLR4 and TLR9 antagonists, and the TLR5
agonists, Entolimod and GP532. TLRs are a class of protein
that plays a key role in the innate immune system. Statera
Biopharma is developing therapies designed to directly elicit
within patients a robust and durable response of antigen-specific
killer T-cells and antibodies, thereby activating essential immune
defenses against autoimmune, inflammatory, infectious diseases, and
cancers. Statera Biopharma has clinical programs for Crohn’s
disease (STAT-201), hematology (Entolimod), pancreatic cancer
(STAT-401) and COVID-19 (STAT-205) in addition to potential
expansion into fibromyalgia and multiple sclerosis. To learn
more about Statera Biopharma, please
visit www.staterabiopharma.com.
Forward Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. All statements other than statements of
current or historical fact contained in this press release,
including statements regarding the Company’s expected clinical
development timeline for the Company’s product candidates, future
financial position, business strategy, new products, budgets,
liquidity, cash flows, projected costs, regulatory approvals, the
impact of any laws or regulations applicable to the Company, and
plans and objectives of management for future operations, are
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “should,” “estimate,” “expect,” “intend,” “may,”
“plan,” “project,” “will,” and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have
based these forward-looking statements on the current expectations
about future events held by management. While we believe these
expectations are reasonable, such forward-looking statements are
inherently subject to risks and uncertainties, many of which are
beyond the Company’s control. The Company’s actual future results
may differ materially from those discussed here for various
reasons. The Company discusses many of these risks under the
heading “Risk Factors” in the proxy statement/prospectus filed with
the SEC on June 10, 2021, as updated by the Company’s other filings
with the SEC.
Given these uncertainties, you should not place
undue reliance on these forward-looking statements. The
forward-looking statements included in this press release are made
only as of the date hereof. We do not undertake any obligation to
update any such statements or to publicly announce the results of
any revisions to any of such statements to reflect future events or
developments.
Contact:Statera
BiopharmaNichol OchsnerExecutive V.P. Investor Relations
and Corporate Communications(732)
754-2545nichol.ochsner@staterabiopharma.com
Statera BioPharma (NASDAQ:STAB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Statera BioPharma (NASDAQ:STAB)
Historical Stock Chart
From Sep 2023 to Sep 2024